SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 milli ...

Core Insights - El Mayor Tequila is launching new 375mL sizes of its Blanco and Reposado expressions to cater to consumer preferences and usage needs [1][2] - The suggested retail price for the new 375mL sizes is set at $14.99, making it more accessible for consumers [2] - A spring cocktail kit priced at $89.99 will also be introduced, featuring a 375mL bottle of El Mayor Reposado along with cocktail ingredients [1] Product Details - El Mayor Tequila is produced at Destiladora Gonzalez Lux in Arandas, Mexico, using 100% estate-grown Blue Weber Agave from Jalisco [3][6] - The Blanco expression is an unaged tequila with a light body and floral notes, while the Reposado is aged for a minimum of nine months in American white oak barrels, offering fruit flavors with vanilla and spice [3] Awards and Recognition - El Mayor Tequila Blanco received gold medals at the 2025 ASCOT awards, the 2025 San Francisco World Spirits Competition, and the 2025 SIP awards [4] - El Mayor Tequila Reposado was awarded a gold medal at the 2025 ASCOT awards and a platinum medal at the 2025 SIP awards, and was recognized as one of the top 10 tequilas in the world at the 2025 International Wines and Spirits Competition [4] Company Background - El Mayor Tequila is part of Luxco, a leading producer and supplier of beverage alcohol products, which has been in operation since 1958 [7] - Luxco operates as MGP Ingredients Inc. (Nasdaq: MGPI) Branded Spirits division since its acquisition in 2021, with a diverse portfolio that includes various premium brands [7]

Core Insights - Supernus Pharmaceuticals is preparing for significant developments in 2025 and beyond, particularly with the acquisition of Sage Therapeutics and new product launches [3] Group 1: Company Developments - The company has achieved FDA approval for new products in July 2025, marking a pivotal moment in its growth strategy [3] - The acquisition of Sage Therapeutics is highlighted as a key accomplishment that will influence the company's positioning for 2026 [3] Group 2: Leadership and Presentation - Glen Santangelo from Barclays Bank PLC is the analyst responsible for the specialty pharmaceutical sector and is leading the presentation [2] - Jack Khattar, the President and CEO of Supernus Pharmaceuticals, is present to discuss the company's recent achievements and future plans [2]

GSK FY Conference Summary Company Overview - **Company**: GSK (NYSE:GSK) - **Date**: March 11, 2026 - **Key Speaker**: David Redfern, Chief Strategy Officer and Chairman of ViiV Core Industry Insights Strategic Direction - GSK is focused on maintaining its strategic direction under new CEO Luke Miels, emphasizing execution, growth, and simplification of the business [4][5] - Key therapy areas include respiratory, inflammation, immunology, oncology, infectious diseases, and vaccines [4][5] Business Development and M&A - GSK has been active in M&A, closing deals with RAPT for food allergy treatment and Thirty-Five Pharma for pulmonary hypertension [7][10] - The RAPT asset is seen as an improved version of Xolair, targeting a significant market of 17 million people in the U.S. [7][8] - The Thirty-Five Pharma deal focuses on a drug for pulmonary hypertension, which is in early clinical stages [10] Pipeline Execution - GSK is concentrating on mid to late-stage assets that will drive growth into the 2030s, with a focus on optimizing R&D processes [6][12] Product Launches and Market Opportunities Exdensur (IL-5 for Severe Asthma) - Exdensur offers a six-month dosing regimen, which is expected to increase biologic penetration in the under-treated severe asthma market [22][24] - The product is anticipated to face standard insurance coverage processes, with no unusual challenges expected [25][26] Nucala (IL-5 for COPD) - Nucala has shown a 35% reduction in exacerbations leading to hospitalizations, addressing a significant unmet medical need in COPD [28] - GSK is exploring additional mechanisms and combinations for COPD treatment, including trials for different severity levels [30] Blenrep (BCMA Agent for Hematological Cancers) - Blenrep has shown promising efficacy, with a significant reduction in risk of death compared to standard care [33] - The launch strategy includes careful training for healthcare providers to ensure positive patient experiences [35][36] HIV Pipeline Developments Long-Acting Treatments - GSK is advancing its six-month treatment options for HIV, with promising data on third-generation integrase and capsid inhibitors [46][47] - The company is focused on developing a best-in-class six-month treatment regimen, with plans for further clinical testing [48] Competitive Landscape - GSK acknowledges the growing PrEP market and the potential impact of competitors like Gilead, but remains confident in the growth of its long-acting product Apretude [58] Additional Insights - GSK is strategically diversifying its portfolio beyond infectious diseases and oncology, focusing on respiratory and inflammation areas [11][12] - The company is leveraging AI for patient stratification in COPD, indicating a sophisticated approach to clinical development [30] Conclusion GSK is positioning itself for future growth through strategic M&A, a robust pipeline focused on mid to late-stage assets, and innovative product launches across various therapeutic areas. The emphasis on execution and simplification under the new CEO is expected to drive the company's performance into the next decade.

Financial Data and Key Metrics Changes - Total revenues for the first half of FY 2026 were $51.3 million, driven by the successful launch of Ryoncil, with net product revenues of $49 million and a gross margin of 93% [7][10] - R&D expenses increased to $46.1 million from $5.1 million in the prior year, primarily due to adult GVHD trials and other programs [7][9] - Sales and general administrative expenses rose to $28.5 million from $18 million in the prior year, reflecting increased sales and marketing efforts [9] - The net loss for the period was $40.2 million, down from $48 million in the prior year [9] Business Line Data and Key Metrics Changes - Ryoncil, the first FDA-approved allogeneic mesenchymal stromal cell product, generated $49 million in net revenue in the first half of FY 2026, with significant market adoption expected [5][36] - The company aims to achieve a 20% market share for Ryoncil in the pediatric population by the end of the fiscal year [15][45] Market Data and Key Metrics Changes - Ryoncil is now covered by insurance plans representing over 280 million lives, with Medicaid coverage in all states and favorable coverage policies from major payers [17] - The company has onboarded 49 treatment centers, with 30 centers listing Ryoncil on their formularies, facilitating adoption [15][16] Company Strategy and Development Direction - The company plans to expand Ryoncil's label indications and seek approval for Revascor and Ryoncil products, focusing on operational efficiency and cash flow management [4][36] - Strategic priorities include identifying appropriate patients for Ryoncil therapy, reinforcing superior patient outcomes, and empowering caregivers [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year Ryoncil net revenues between $110 million and $120 million, supported by ongoing market adoption and operational efficiencies [12][36] - The company is optimistic about the potential for Ryoncil in adult indications and other inflammatory diseases, with ongoing clinical trials [20][21] Other Important Information - The company entered into a $125 million non-dilutive credit line facility, enhancing financial flexibility and supporting growth initiatives [12][13] - The company is actively optimizing manufacturing logistics to support commercialization of both Ryoncil and its second-generation products [36] Q&A Session Summary Question: Guidance for the upcoming year - The company projects full fiscal year net revenues ranging from $110 million to $120 million [41] Question: Ryoncil penetration in pediatrics - The company aims for a 20% penetration of the pediatric population by the end of the fiscal year, based on a patient range of 300 to 375 [45][46] Question: Revascor BLA submission details - The company plans to submit data from the ongoing phase three trial as the primary dataset, with previous trials serving as supportive data [55] Question: Chronic back pain trial data submission - The ongoing phase three trial will be included in the filing, with the aim to complete enrollment soon [56][68]

Financial Data and Key Metrics Changes - Consolidated shipments for 2025 were 5.5 million units, up 1% year-over-year, with increases in South America, North America, and the Middle East and Africa [7] - Net revenues were EUR 153 billion, a decrease of 2% year-over-year, with an AOI margin of negative 0.5% reflecting early recovery stages and substantial net tariff expenses [7][8] - Industrial free cash flow saw outflows of EUR 4.5 billion for the full year, but H2 2025 showed a 50% sequential improvement compared to H1 2025 [9][10] Business Line Data and Key Metrics Changes - North America posted a 39% increase in shipments and a 31% increase in revenues in H2 2025, driven by normalized inventory dynamics and higher sales [10][11] - In Enlarged Europe, H2 AOI decreased due to a higher LEV mix and net pricing decline amid a competitive environment [11] - South America experienced a decline in AOI due to increased costs, while the Middle East and Africa saw solid growth in shipments [11] Market Data and Key Metrics Changes - U.S. market share increased year-over-year in January 2026, with European shares also seeing a sequential increase compared to H2 2025 [5] - The order portfolio in North America and Europe combined was up 46%, with North America up 150% and Europe up 18% [16] - South America maintained its number one share position, with the Ram Dakota launched in Argentina and set to launch in Brazil [24] Company Strategy and Development Direction - The company is focused on a decisive reset to put the customer at the center, aiming for profitable growth and execution in 2026 [4][18] - A $13 billion investment over four years is planned to improve market coverage and manufacturing utilization in the U.S., introducing new vehicles and renewing the current lineup [17] - The company is integrating the Maserati business into regional segments to enhance operational efficiency and regional focus [12][54] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging environment in Europe due to unclear regulations, but strong demand for STLA AutoDrive products is expected to support profit building in 2026 [29] - In North America, the company anticipates market share growth and new product launches to drive profitability, particularly with the HEMI V8 engine [30] - The company expects to see progressive performance improvements across all business KPIs in 2026 [25] Other Important Information - The company confirmed its 2026 financial guidance and will start reporting full-year earnings results quarterly [12] - A significant focus on quality improvements has been established, with over 2,000 new engineers hired to drive enhancements [15][63] - The company plans to address competitive pressures in pricing, particularly in Europe, while maintaining a stable pricing environment in North America [80] Q&A Session Summary Question: Need for larger restructuring measures in Europe - Management acknowledged the need for restructuring but highlighted strong demand and a large order portfolio as foundations for profit building in 2026 [29] Question: Operating leverage in North America - Management indicated strong growth in volume and pricing, with expectations for improved mix and profitability in 2026 [35] Question: Revenue growth outlook for 2026 - Management forecasted a slight decline in the North American market and flat conditions in Europe, with growth driven by new vehicle launches [43] Question: Positive AOI in North America for 2026 - Management confirmed that North America is expected to be the largest contributor to profitable growth in 2026 [49] Question: CapEx and investment levels - Management confirmed that investments are expected to remain flat year-over-year, focusing on areas with the highest return potential [55] Question: Quality development trends - Management reported significant improvements in quality metrics across regions, with ongoing efforts to enhance quality further [63]

Product Launch Insights - The company is planning significant product launches in the first half of the year, with a focus on a new low-cost MacBook priced between $700 to $900, which will be powered by an iPhone chip and slightly smaller than the MacBook Air [2][3] - The new low-cost MacBook has the potential to overshadow Chromebooks and some Windows PCs currently on the market, indicating a strong competitive position [4] - Additional products expected to be launched include new MacBook Pros, new MacBook Airs, the iPhone 17e, and new entry-level and iPad Air models [4] Event Significance - The company is hosting in-person events in major metropolitan areas such as London, Shanghai, and New York, suggesting the significance of the upcoming product launches [2] - The expectation is that at least the iPhone 17e will be unveiled at the event, highlighting the importance of this product in the company's lineup [5] Product Availability - New products typically hit the shelves quickly after announcement, with spec bumps rolling out within a few days, and the maximum delay being about one to two weeks [6]

Group 1 - Apple Inc. will hold a "special Apple Experience" event on March 4 in New York, London, and Shanghai, showcasing a 3D Apple logo in the invitation [1] - The event is expected to be more intimate than typical live-streamed events and will unveil multiple new products, including the iPhone 17e, MacBook Pro with M5 Pro and M5 Max chips, eighth-generation iPad Air, and 12th-generation iPad [1] - Additional possible launches may include an updated Studio Display, a budget-friendly MacBook with the A18 chip, a new Apple TV, and a HomePod mini [2] Group 2 - Apple is preparing for significant product launches in 2026, focusing on premium iPhone models while delaying standard models due to memory chip constraints [3] - Benzinga's Edge Rankings place Apple in the 94th percentile for quality and the 51st percentile for momentum, indicating mixed performance [4] - Year-to-date, Apple stock has declined by 5.62%, closing at $255.78 after a 2.27% drop on the previous Friday [4]

Core Insights - The launch of the Pullmaster® 40 M/H Planetary Winch marks a significant milestone for the M & H Series, designed for demanding marine, industrial, recovery, energy, and natural resources applications [1][2] Product Overview - The Pullmaster 40 M/H Planetary Winch is engineered to meet the needs of customers requiring a winch with a pulling capacity greater than 25,000 pounds but smaller than the existing 50,000-pound model, filling a critical gap in the product lineup [3][4] - This new winch maintains the brand's commitment to robust engineering, operational reliability, and long-term serviceability, while introducing differentiating features that enhance its performance in harsh environments [2][4] Company Background - Pullmaster is recognized as a leading manufacturer of hydraulic winches and hoists, known for durable designs and reliable performance in demanding industrial applications [5] - TWG, the parent company of Pullmaster, offers a wide range of products across multiple model lines, with over one million units installed, showcasing its extensive experience in the industry [6] Parent Company Information - Dover, the parent company of TWG, is a diversified global manufacturer with annual revenue exceeding $7 billion, operating across five segments and employing approximately 24,000 individuals [7]

Core Insights - The company is pleased with its execution throughout the year, particularly in fiscal Q3, highlighting successful product launches and a strong replacement cycle [1] - Key product launches include the Pro iQ single-quad and the 8850, which have resonated well in the market [1] - The Infinity III replacement cycle has also contributed positively to the overall performance [1] Services Business - The services business is critical for the company, emphasizing the importance of customer connection and satisfaction in driving performance [2] - Four key areas have been identified as significant contributors to the company's success, with a particular focus on the CDMO business [2]